MedKoo Cat#: 121217 | Name: BAY4931
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BAY-4931 is a selective covalent inverse agonist of PPARγ, developed by Bayer and the Broad Institute to investigate gene regulation in cancer and metabolism. It binds the PPARγ ligand-binding domain and promotes corepressor recruitment, suppressing transcription of target genes. BAY-4931 exhibits nanomolar potency and high selectivity, making it a powerful research tool for studying PPARγ-driven pathways.

Chemical Structure

BAY4931
BAY4931
CAS#423150-91-8

Theoretical Analysis

MedKoo Cat#: 121217

Name: BAY4931

CAS#: 423150-91-8

Chemical Formula: C22H16ClN3O4

Exact Mass: 421.0829

Molecular Weight: 421.84

Elemental Analysis: C, 62.64; H, 3.82; Cl, 8.40; N, 9.96; O, 15.17

Price and Availability

Size Price Availability Quantity
50mg USD 550.00 2 Weeks
100mg USD 850.00 2 Weeks
200mg USD 1,350.00 2 Weeks
500mg USD 2,650.00 2 Weeks
1g USD 3,450.00 2 Weeks
2g USD 5,950.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
BAY4931; BAY-4931; BAY 4931
IUPAC/Chemical Name
2-chloro-N-(2-(4-ethylphenyl)benzo[d]oxazol-5-yl)-5-nitrobenzamide
InChi Key
WFEBALYYDASKIV-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H16ClN3O4/c1-2-13-3-5-14(6-4-13)22-25-19-11-15(7-10-20(19)30-22)24-21(27)17-12-16(26(28)29)8-9-18(17)23/h3-12H,2H2,1H3,(H,24,27)
SMILES Code
ClC1=CC=C([N+]([O-])=O)C=C1C(NC2=CC(N=C(C3=CC=C(CC)C=C3)O4)=C4C=C2)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
The ligand-activated nuclear receptor peroxisome-proliferator-activated receptor-γ (PPARG or PPARγ) represents a potential target for a new generation of cancer therapeutics, especially in muscle-invasive luminal bladder cancer where PPARγ is a critical lineage driver.

Preparing Stock Solutions

The following data is based on the product molecular weight 421.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Orsi DL, Pook E, Bräuer N, Friberg A, Lienau P, Lemke CT, Stellfeld T, Brüggemeier U, Pütter V, Meyer H, Baco M, Tang S, Cherniack AD, Westlake L, Bender SA, Kocak M, Strathdee CA, Meyerson M, Eis K, Goldstein JT. Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069. J Med Chem. 2022 Nov 10;65(21):14843-14863. doi: 10.1021/acs.jmedchem.2c01379. Epub 2022 Oct 21. PMID: 36270630.